Moreover, it is known that cancer cells with high tumour antigen loads may avoid presenting neoantigens on the surface of MHC, through altering the antigen presenting machinery such as proteasome subunits or transporters associated with antigen processing (TAP), beta-2-microglobulin (B2M) or MHC itself (45, 46). Here, B2M is linked to cancer.